Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WILLOW TREE: Aspirin Dose Modification on Innate Immune Response
NCT03869268Phase 4Completed
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Apr 2019
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in acute coronary syndrome (ACS) (8 arms), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Assess Inflammatory Response to Intravenous Endotoxin. Started Apr 2019; status: completed.
02
Drugs
aspirin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03869268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869268.